2-甲基-1H-吡咯并[2,3-B]吡啶-3-甲醛 | 858275-30-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 2-甲基-1H-吡咯并[2,3-B]吡啶-3-甲醛
• 英文名称: 2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde
• 英文别名: 2-Methyl-1H-pyrrolo[2,3-b]pyridin-3-carbaldehyd
• CAS: 858275-30-6
• 化学式: C₉H₈N₂O
• mdl: MFCD11616737
• 分子量: 160.175
• InChiKey: DXESDXYYNGHALB-UHFFFAOYSA-N

物化性质

• 熔点：
  210-212 °C(Solv: hexane (110-54-3))
• 密度：
  1.301±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H317,H319,H335

反应信息

• 作为反应物：
  描述：

  2-甲基-1H-吡咯并[2,3-B]吡啶-3-甲醛 在 盐酸羟胺 、 碳酸氢钠 作用下， 以 水 为溶剂， 反应 4.5h， 以69%的产率得到2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde oxime
  参考文献：
  名称：

  Synthesis and antidiabetic activity of 2,5-disubstituted-3-imidazol-2-yl-pyrrolo[2,3-b]pyridines and thieno[2,3-b]pyridines

  摘要：

  In the present investigation, two series of 2,5-disubstituted-3-imidazol-2-yl-pyrrolo[2,3-b]pyridines (2a-1) and thieno[2,3-b]pyridines (3a-1) were designed as analogs of BL 11282 (1). The in vitro glucose dependent insulinotropic activity of all the test compounds was evaluated using RIN5F cell based assay and all the test compounds showed glucose and concentration dependent insulin secretion. The in vivo antidiabetic activities of most potent compounds from each series (2c and 3c) were assessed in C57BL/6J mice. Compounds 2c and 3c showed dose dependent insulin secretion and significant glucose reduction in vivo. In general, compounds 2c and 3c were found to be equipotent at all the three different doses selected and with respect to BL 11282, both the test compounds were found to be more potent, at all the time points. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.08.005
• 作为产物：
  描述：

  3-甲基-2-乙酰氨基吡啶 在 氢氧化钾 、 乙醇 、 氯仿 、 sodium ethanolate 作用下， 生成 2-甲基-1H-吡咯并[2,3-B]吡啶-3-甲醛
  参考文献：
  名称：

  163.对尼古丁和7-氮杂吲哚及其衍生物合成的研究作出了贡献

  摘要：

  DOI：

  10.1039/jr9450000603

文献信息

• NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7
  申请人：Leroy Vincent

  公开号：US20090253679A1

  公开（公告）日：2009-10-08

  The present invention relates to imidazolone derivatives of formula (I) to methods of preparing such derivatives, intermediates thereto, pharmaceutical compositions comprising such derivatives, and methods of inhibiting protein kinase, and methods of treatment comprising administration of such derivatives.

  本发明涉及式(I)的咪唑酮衍生物，涉及制备这种衍生物的方法、中间体、包含这种衍生物的药物组合物、抑制蛋白激酶的方法以及包括给予这种衍生物的治疗方法。
• NOUVEAUX DERIVES IMIDAZOLONES, LEUR PREPARATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES, UTILISATION COMME INHIBITEURS DE PROTEINES KINASES NOTAMMENT CDC7
  申请人：Sanofi-Aventis

  公开号：EP2094699B1

  公开（公告）日：2011-07-20
• US8314121B2
  申请人：——

  公开号：US8314121B2

  公开（公告）日：2012-11-20
• [EN] NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7<br/>[FR] NOUVEAUX DERIVES IMIDAZOLONES, LEUR PREPARATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES, UTILISATION COMME INHIBITEURS DE PROTEINES KINASES NOTAMMENT CDC7
  申请人：SANOFI AVENTIS

  公开号：WO2008046982A2

  公开（公告）日：2008-04-24

  [EN] The invention relates to products of the formula (I) in which : X-Y is NH-C(S), N=C-NR7R8, N=C-SR, N=C-R or N=C-OR; R and R1 are H or optionally substituted cycloalkyl, alkyl, heterocycloalkyl, aryl or heteroaryl,; R2 is H, Hal or alkyl; R3 is H, Hal, OH, alkyl or alkoxy; R4 is H, Hal, CN or alkyl; R5 is essentially H, Hal, OH, NR7R8, cycloalkyl, alkyl, alkoxy, heterocycloalkyl, aryl or heteroaryl, optionally substituted; R6 is H, Hal, OH, NH2, NHalk, N(alk)2, alkyl or alkoxy; with R7 et R8 being such that one is H or optionally substituted alk, while the other is H or optionally substituted cycloalkyl, alkyl, heterocycloalkyl, heteroaryl or aryl; or with R7 and R8 forming together with N an optionally substituted cyclic radical optionally containing O, S or N. The invention also relates to isomers and salts thereof used as drugs and essentially as protein kinase inhibitors, in particular CDC7.
  [FR] L'invention concerne les produits de formule (I): avec X-Y représente NH-C(S), N=C-NR7R8, N=C-SR, N=C-R ou N=C-OR; R et R1 représente H, cycloalkyle, alkyle, hétérocycloalkyle, aryle ou hétéroaryle, éventuellement substitués; R2 représente H, Hal ou alkyle; R3 représente H, Hal, OH, alkyle ou alcoxy; R4 représente H, Hal, CN ou alkyle; R5 représente notamment H, Hal, OH, NR7R8, cycloalkyle, alkyle, alcoxy, hétérocycloalkyle, aryle ou hétéroaryle, éventuellement substitués; R6 représente H, Hal, OH, NH2, NHalk, N(alk)2, alkyle ou alcoxy; avec R7 et R8 tels que l'un représente H ou alk éventuellement substitué; et l'autre représente H, cycloalkyle, alkyle, hétérocycloalkyle, hétéroaryle ou aryle, éventuellement substitués; ou bien R7 et R8 forment ensemble avec N un radical cyclique, renfermant éventuellement O, S ou N, éventuellement substitué; leurs isomères et leurs sels, comme médicaments notamment comme inhibiteurs de kinases et particulièrement de CDC7.
• [EN] PYRROLOPYRIDINE CARBOXYLIC ACID DERIVATIVES<br/>[FR] DÉRIVÉS ACIDE CARBOXYLIQUE DE PYRROLOPYRIDINE
  申请人：IRONWOOD PHARMACEUTICALS INC

  公开号：WO2010005528A2

  公开（公告）日：2010-01-14

  Disclosed are compounds and pharmaceutically acceptable salts of Formula (I) wherein R1, R2, R3, and RN are as defined herein. Compounds of Formula (I) are useful in the prevention and/or treatment of neurological and psychiatric disorder, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the disclosure and methods of treating the aforementioned conditions using such compounds.